Boston Scientific revenue and financials
$42.19Change from previous close: −0.50%Absolute change: −$0.21
In the fiscal year ended December 2025, Boston Scientific reported revenue of $20.07B (+19.87% year over year). Net income was $2.89B, a net margin of 14.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +19.87%
- 2025 vs 2024
- Net income growth
- +56.66%
- 2025 vs 2024
- Net margin
- 14.4%
- 2024: 11.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,474 | 348 | 1,364 | 1,343 | 1,286 | 541 | 1,456 | 1,002 | 813 | 164 | 957 | 698 |
| Depreciation and amortization | 355 | 351 | 365 | 342 | 336 | 325 | 348 | 306 | 311 | 304 | 313 | 300 |
| Capital expenditure | -195 | -177 | -351 | -181 | -157 | -187 | -277 | -179 | -155 | -179 | -267 | -190 |
| Investing cash flow | -1,956 | -591 | -512 | -502 | -1,126 | -500 | -3,704 | -1,427 | -271 | -285 | -1,053 | -197 |
| Financing cash flow | -410 | -260 | -184 | -104 | -340 | 233 | 214 | 7.0 | 24.0 | 1,569 | 15.0 | 16.0 |
| Share repurchases | -2,000 | — | — | — | — | — | — | — | — | — | — | — |
| Debt issued | 1,675 | 0.0 | 0.0 | -1.0 | 1.0 | 1,558 | 187 | — | — | 2,145 | — | -37.0 |
| Debt repaid | -13.0 | -259 | -209 | -215 | -314 | -1,311 | — | — | — | -529 | — | -4.0 |
| Effect of exchange rates | 1.0 | 0.0 | 3.0 | -2.0 | 2.0 | 39.0 | -9.0 | 6.0 | -1.0 | -7.0 | 4.0 | -5.0 |
| Net change in cash | -890 | -504 | 671 | 735 | -178 | 313 | -2,044 | -413 | 566 | 1,441 | -77.0 | 513 |
| Free cash flow | 1,279 | 171 | 1,013 | 1,162 | 1,129 | 354 | 1,179 | 823 | 658 | -15.0 | 690 | 508 |
| Levered free cash flow | 866 | -51.3 | 815 | 725 | 1,164 | 383 | 619 | 607 | 550 | -124 | 620 | 427 |